Tensions have run high in the multidistrict litigation over Boehringer Ingelheim GmbH’s drug Pradaxa, to the point where Boehringer once sought a court order barring plaintiffs counsel from harassing company employees during depositions. But with a bellwether trial approaching, the legal teams have put aside their resentments and worked out a comprehensive settlement.
Boehringer announced Wednesday that it’s paying $650 million to settle about 4,000 personal injury lawsuits relating to Pradaxa, a blood thinner alleged to have caused bleed-out deaths among patients. Those cases were consolidated into an MDL before U.S. District Judge David Herndon in East St. Louis, Ill. The first trial was scheduled for September.
